Navigation Links
CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
Date:8/19/2008

VIENNA, Va., Aug. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) announced today that it has entered into an exclusive licensing agreement with Teva Pharmaceutical Industries Ltd. (Teva), a leading global pharmaceutical company, under which CEL-SCI has granted Teva an exclusive license to market and distribute the Company's cancer drug Multikine for Israel and Turkey (the "Territory"). The licensing agreement is initially restricted to the areas of head and neck cancer. Teva has the right, subject to certain conditions, to extend the licensing agreement to include other cancers during the term of this agreement. Multikine is currently thought to be potentially useful in treating many tumor types.

Pursuant to the agreement, Teva will participate in CEL-SCI's upcoming global Phase III clinical trial. Teva will fund a portion of the Phase III clinical study and Teva's clinical group will conduct part of the clinical study in Israel under the auspices of CEL-SCI and its Clinical Research Organization. Teva will also be responsible for registering the product in the Territory. Once Multikine has been approved, CEL-SCI will be responsible for manufacturing the product, while Teva will be responsible for sales in the Territory. Revenues will be split 50/50 between CEL-SCI and Teva.

"We believe that Teva's expertise and knowledge in successfully conducting large pivotal clinical trials and in developing markets for large unmet medical needs will prove invaluable in maximizing Multikine's potential. This agreement is consistent with our strategy to share the clinical and regulatory expenses associated with the development of Multikine while retaining rights to market Multikine in North America and Europe," said Geert Ker
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... in part) in, into or from any jurisdiction where to ... of such jurisdiction.  Shire plc ("Shire" or the ... Bloomberg article this afternoon.  Shire confirms it has held a ... being made by Shire without the prior agreement or approval ...
(Date:7/11/2014)...  Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/10/2014)... July 10, 2014 Understanding the need ... cell lines, and the gap that currently exists in ... expand its industry-leading portfolio of validated ion channel and ... channel-expressing cell lines, as ion channels control many critical ... this activity creates the potential to treat a variety ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... With all the domestic and global issues going on ... the world's leaders viewed issues in yesterday's critical moments. ... had to shoulder huge responsibilities. They are worth applying ... perspectives may help broaden your view of things. That's ...
... startup and spin-off companies are gaining attention from ... of this is Primorigen Biosciences LLC , ... analysis of cellular reprogramming and differentiation. , ,Primorigen, ... related products, will use a pair of investments ...
... Wis. - Norlight Telecommunications, Inc., which ... announced that it will roll out its new Voice ... businesses in Green Bay and Madison. , ,The ... growth market by offering integrated communications bundles of local ...
Cached Biology Technology:Business leaders can learn from historical insights 2Business leaders can learn from historical insights 3Business leaders can learn from historical insights 4Business leaders can learn from historical insights 5Wisconsin start up Primorigen Biosciences corrals out-of-state investment 2Norlight will offer VoIP in Madison, Green Bay 2
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
(Date:7/11/2014)... Using spider toxins to study the proteins that let ... say they have stumbled upon a biological tactic that ... insect plagues in a safe and environmentally responsible way. ... be lethal for one species and harmless for a ... target specific pests without harming beneficial species like bees. ...
(Date:7/10/2014)... COLORADO SPRINGS, Colo. , June 27, 2014 ... announces that the National Institute of Standards and ... appointed 10 of its academic research and forensic ... Board (FSSB).  The Board is an element of ... These AAFS members are among the first appointments ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3
... state of chronic inflammation. If chronic, the inflammation will ... devastating disease multiple sclerosis, hyperactivity of immune cells called ... Researchers at BRIC, the University of Copenhagen, have identified ... combat such hyperactive T-cells in blood from patients with ...
... Lincoln, Neb., Feb. 17, 2014 -- Fertilizer could be too much ... findings to be published online Feb. 16 by the journal ... nitrogen will increase the amount of grass that can be grown. ... are better adapted to survive in harsher times. It results in ...
... why skeletal muscle stem cells stop dividing and renewing ... opportunity for managing muscle-wasting conditions in humans, says a ... to CU-Boulder Professor Bradley Olwin, the loss of skeletal ... to sarcopenia, a debilitating muscle-wasting condition that generally hits ...
Cached Biology News:New blood cells fight brain inflammation 2Worldwide study finds that fertilizer destabilizes grasslands 2CU-Boulder stem cell research may point to new ways of mitigating muscle loss 2CU-Boulder stem cell research may point to new ways of mitigating muscle loss 3
... protein assay reagents package is used for determining ... and detergents. The RC DC protein assay is ... for 500 standard assays: 250 ml RC reagent ... alkaline copper tartrate solution, 2 L dilute Folin ...
... SureLINK Bioconjugation Kit provides a powerful ... carbohydrates and nuceleic acids. The kit provides ... with reagents for quantifying conjugation efficiencies. It ... fluorophores, biotin and other tags with a ...
...
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Biology Products: